Remote ischaemic conditioning: defining critical criteria for success—report from the 11th Hatter Cardiovascular Workshop

Autor: R. M. Bell, M. Basalay, H. E. Bøtker, S. Beikoghli Kalkhoran, R. D. Carr, J. Cunningham, S. M. Davidson, T. J. England, S. Giesz, A. K. Ghosh, P. Golforoush, A. V. Gourine, D. J. Hausenloy, G. Heusch, B. Ibanez, P. Kleinbongard, S. Lecour, K. Lukhna, M. Ntsekhe, M. Ovize, A. D. Salama, G. Vilahur, J. M. Walker, D. M. Yellon

Publikováno v: Bell, R M, Basalay, M, Bøtker, H E, Beikoghli Kalkhoran, S, Carr, R D, Cunningham, J, Davidson, S M, England, T J, Giesz, S, Ghosh, A K, Golforoush, P, Gourine, A V, Hausenloy, D J, Heusch, G, Ibanez, B, Kleinbongard, P, Lecour, S, Lukhna, K, Ntsekhe, M, Ovize, M, Salama, A D, Vilahur, G, Walker, J M & Yellon, D M 2022, ' Remote ischaemic conditioning : defining critical criteria for success—report from the 11th Hatter Cardiovascular Workshop ', Basic Research in Cardiology, vol. 117, no. 1, 39 . https://doi.org/10.1007/s00395-022-00947-2
BASIC RESEARCH IN CARDIOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

The Hatter Cardiovascular Institute biennial workshop, originally scheduled for April 2020 but postponed for 2 years due to the Covid pandemic, was organised to debate and discuss the future of Remote Ischaemic Conditioning (RIC). This evolved from t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0c01bb37bd518d8290a572a8f910e38
https://doi.org/10.1007/s00395-022-00947-2

Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation

Autor: M, Schmidt, M B, Johansen, D J, Robertson, M, Maeng, A, Kaltoft, L O, Jensen, H-H, Tilsted, H E, Bøtker, H T, Sørensen, J A, Baron

Publikováno v: Alimentary pharmacologytherapeutics. 35(1)

Cytochrome P450 inhibition by proton pump inhibitors (PPIs) may attenuate the effectiveness of clopidogrel.To examine whether PPI use modifies the association between clopidogrel use and major adverse cardiovascular events (MACE) after percutaneous c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a17508bae90ce9edb945c75be3288a8b
https://pubmed.ncbi.nlm.nih.gov/22172084

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease

Autor: J P, Bagger, H E, Bøtker, A, Thomassen, T T, Nielsen

Publikováno v: Cardiovascular drugs and therapy. 11(3)

Cytoprotection or metabolic modulation is a new principle in the treatment of angina pectoris. The effect of ranolazine (a cytoprotective drug) on ischemic threshold, coronary sinus blood flow, and myocardial metabolism was evaluated by means of two

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::571dbfd179357e37ac59d50365fce6fe
https://pubmed.ncbi.nlm.nih.gov/9310277

[Hyperthyroidism and heart disease. Is thyrotoxic cardiomyopathy a disease entity?]

Autor: P, Toft, H E, Bøtker

Publikováno v: Ugeskrift for laeger. 155(18)

Cardiac symptoms have a prominent position in hyperthyroidism. The basic haemodynamic change is an increased cardiac output due to an increased stroke volume and an increased heart rate. Dyspnoea and palpitations are frequent symptoms. ECG-changes su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a24d67bab04a68aa06885a183fac4298
https://pubmed.ncbi.nlm.nih.gov/8497965